Taro Pharmaceutical Industries Ltd. (NYSE:TARO) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

A number of other analysts have also issued reports on TARO. Credit Suisse Group lowered Taro Pharmaceutical Industries from an “outperform” rating to a “neutral” rating in a research report on Tuesday, May 23rd. TheStreet lowered Taro Pharmaceutical Industries from a “b-” rating to a “c” rating in a research report on Thursday, June 15th.

Shares of Taro Pharmaceutical Industries (NYSE:TARO) traded up 0.92% on Friday, reaching $98.15. The company had a trading volume of 83,300 shares. Taro Pharmaceutical Industries has a 1-year low of $92.28 and a 1-year high of $137.98. The company’s 50 day moving average price is $113.86 and its 200-day moving average price is $112.80. The stock has a market capitalization of $3.97 billion, a P/E ratio of 9.99 and a beta of 0.64.

Taro Pharmaceutical Industries (NYSE:TARO) last announced its earnings results on Monday, May 22nd. The company reported $2.05 earnings per share (EPS) for the quarter. The company had revenue of $196.41 million for the quarter. Taro Pharmaceutical Industries had a return on equity of 20.08% and a net margin of 49.69%. Equities analysts predict that Taro Pharmaceutical Industries will post $9.49 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Taro Pharmaceutical Industries Ltd. (NYSE:TARO) Stock Rating Lowered by BidaskClub” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/11/taro-pharmaceutical-industries-ltd-nysetaro-stock-rating-lowered-by-bidaskclub.html.

Hedge funds have recently made changes to their positions in the stock. Bank of Montreal Can raised its stake in shares of Taro Pharmaceutical Industries by 7.5% in the second quarter. Bank of Montreal Can now owns 2,128 shares of the company’s stock worth $238,000 after buying an additional 149 shares during the last quarter. NN Investment Partners Holdings N.V. raised its stake in shares of Taro Pharmaceutical Industries by 2.0% in the second quarter. NN Investment Partners Holdings N.V. now owns 53,976 shares of the company’s stock worth $6,049,000 after buying an additional 1,064 shares during the last quarter. Creative Planning raised its stake in shares of Taro Pharmaceutical Industries by 3.8% in the second quarter. Creative Planning now owns 7,186 shares of the company’s stock worth $805,000 after buying an additional 265 shares during the last quarter. Aperio Group LLC raised its stake in shares of Taro Pharmaceutical Industries by 46.9% in the second quarter. Aperio Group LLC now owns 50,826 shares of the company’s stock worth $5,696,000 after buying an additional 16,233 shares during the last quarter. Finally, US Bancorp DE raised its stake in shares of Taro Pharmaceutical Industries by 49.4% in the second quarter. US Bancorp DE now owns 2,983 shares of the company’s stock worth $334,000 after buying an additional 986 shares during the last quarter. 16.41% of the stock is currently owned by institutional investors.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.